175 related articles for article (PubMed ID: 33330656)
1. Red Blood Cell Distribution Width Is a Predictive Factor of Anthracycline-Induced Cardiotoxicity.
Yaegashi D; Oikawa M; Yokokawa T; Misaka T; Kobayashi A; Kaneshiro T; Yoshihisa A; Nakazato K; Ishida T; Takeishi Y
Front Cardiovasc Med; 2020; 7():594685. PubMed ID: 33330656
[No Abstract] [Full Text] [Related]
2. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.
Narayan HK; French B; Khan AM; Plappert T; Hyman D; Bajulaiye A; Domchek S; DeMichele A; Clark A; Matro J; Bradbury A; Fox K; Carver JR; Ky B
JACC Cardiovasc Imaging; 2016 Oct; 9(10):1131-1141. PubMed ID: 27085442
[TBL] [Abstract][Full Text] [Related]
3. Ventricular Sigmoid Septum as a Risk Factor for Anthracycline-Induced Cancer Therapeutics-Related Cardiac Dysfunction in Patients With Malignant Lymphoma.
Nakayama T; Oshima Y; Shintani Y; Yamamoto J; Yokoi M; Ito T; Wakami K; Kitada S; Goto T; Hashimoto H; Kusumoto S; Sugiura T; Iida S; Seo Y
Circ Rep; 2022 Apr; 4(4):173-182. PubMed ID: 35434414
[No Abstract] [Full Text] [Related]
4. Non-cardiac factors for prediction of response to cardiac resynchronization therapy: The value of baseline, and of serial changes, in red cell distribution width.
Carluccio E; Biagioli P; Alunni G; Murrone A; Zingarini G; Coiro S; D'Antonio A; Mengoni A; Cerasa MF; Ambrosio G
Int J Cardiol; 2017 Sep; 243():347-353. PubMed ID: 28600101
[TBL] [Abstract][Full Text] [Related]
5. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
6. D-Dimer Is a Predictive Factor of Cancer Therapeutics-Related Cardiac Dysfunction in Patients Treated With Cardiotoxic Chemotherapy.
Oikawa M; Yaegashi D; Yokokawa T; Misaka T; Sato T; Kaneshiro T; Kobayashi A; Yoshihisa A; Nakazato K; Ishida T; Takeishi Y
Front Cardiovasc Med; 2021; 8():807754. PubMed ID: 35127869
[TBL] [Abstract][Full Text] [Related]
7. The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy.
Laufer-Perl M; Arnold JH; Mor L; Amrami N; Derakhshesh M; Moshkovits Y; Sadeh B; Arbel Y; Topilsky Y; Rozenbaum Z
Clin Res Cardiol; 2020 Feb; 109(2):255-262. PubMed ID: 31214777
[TBL] [Abstract][Full Text] [Related]
8. An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline.
Chang WT; Liu CF; Feng YH; Liao CT; Wang JJ; Chen ZC; Lee HC; Shih JY
Arch Toxicol; 2022 Oct; 96(10):2731-2737. PubMed ID: 35876889
[TBL] [Abstract][Full Text] [Related]
9. Cardio-toxicity among patients with sarcoma: a cardio-oncology registry.
Shamai S; Rozenbaum Z; Merimsky O; Derakhshesh M; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Laufer-Perl M
BMC Cancer; 2020 Jun; 20(1):609. PubMed ID: 32605637
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.
Oikonomou EK; Kokkinidis DG; Kampaktsis PN; Amir EA; Marwick TH; Gupta D; Thavendiranathan P
JAMA Cardiol; 2019 Oct; 4(10):1007-1018. PubMed ID: 31433450
[TBL] [Abstract][Full Text] [Related]
11. Activation recovery interval as an electrocardiographic repolarization index to detect doxorubicin-induced cardiotoxicity.
Kinoshita T; Onda N; Ohno R; Ikeda T; Sugizaki Y; Ohara H; Nakagami T; Yuzawa H; Shimada H; Shimizu K; Ikeda T
J Cardiol; 2023 Dec; 82(6):473-480. PubMed ID: 37506822
[TBL] [Abstract][Full Text] [Related]
12. Red cell distribution width and its relationship with global longitudinal strain in patients with heart failure with reduced ejection fraction: a study using two-dimensional speckle tracking echocardiography.
Eroglu E; Kilicgedik A; Kahveci G; Bakal RB; Kirma C
Kardiol Pol; 2018; 76(3):580-585. PubMed ID: 29297194
[TBL] [Abstract][Full Text] [Related]
13. Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial.
Negishi T; Thavendiranathan P; Negishi K; Marwick TH;
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1098-1105. PubMed ID: 29909105
[TBL] [Abstract][Full Text] [Related]
14. Impact of hypertension on left ventricular function in patients after anthracycline chemotherapy for malignant lymphoma.
Tanaka Y; Tanaka H; Hatazawa K; Yamashita K; Sumimoto K; Shono A; Suzuki M; Yokota S; Suto M; Mukai J; Takada H; Matsumoto K; Minami H; Hirata KI
Int J Cardiol; 2021 Jan; 323():126-132. PubMed ID: 32800904
[TBL] [Abstract][Full Text] [Related]
15. Cancer Therapeutics-Related Cardiac Dysfunction among Patients with Active Breast Cancer: A Cardio-Oncology Registry.
Laufer-Perl M; Mor L; Milwidsky A; Derakhshesh M; Amrami N; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Rozenbaum Z
Isr Med Assoc J; 2020 Sep; 22(9):564-568. PubMed ID: 33236555
[TBL] [Abstract][Full Text] [Related]
16. Combined Value of Red Blood Cell Distribution Width and Global Registry of Acute Coronary Events Risk Score for Predicting Cardiovascular Events in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Zhao N; Mi L; Liu X; Pan S; Xu J; Xia D; Liu Z; Zhang Y; Xiang Y; Yuan Z; Guan G; Wang J
PLoS One; 2015; 10(10):e0140532. PubMed ID: 26468876
[TBL] [Abstract][Full Text] [Related]
17. Time course of hypertension and myocardial dysfunction following anthracycline chemotherapy in pediatric patients.
Jacquemyn X; Zhan J; Van den Eynde J; Cordrey K; Long R; Rao S; Barnes BT; Thompson WR; Danford D; Kutty S
Int J Cardiol Heart Vasc; 2024 Aug; 53():101436. PubMed ID: 38872982
[TBL] [Abstract][Full Text] [Related]
18. Cardiac computed tomography-derived extracellular volume fraction in late anthracycline-induced cardiotoxicity.
Egashira K; Sueta D; Tomiguchi M; Kidoh M; Oda S; Usuku H; Hidaka K; Goto-Yamaguchi L; Sueta A; Komorita T; Takae M; Oike F; Fujisue K; Yamamoto E; Hanatani S; Takashio S; Arima Y; Araki S; Kaikita K; Matsushita K; Yamamoto Y; Hirai T; Tsujita K
Int J Cardiol Heart Vasc; 2021 Jun; 34():100797. PubMed ID: 34041357
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines.
Coutinho Cruz M; Moura Branco L; Portugal G; Galrinho A; Timóteo AT; Rio P; Ilhão Moreira R; Mendonça T; Leal A; Gameiro F; Duarte Oliveira S; Luz R; Cruz Ferreira R
Clin Res Cardiol; 2020 Jun; 109(6):673-684. PubMed ID: 31559482
[TBL] [Abstract][Full Text] [Related]
20. Cardiac mechanics and dysfunction with anthracyclines in the community: results from the PREDICT study.
Narayan HK; Wei W; Feng Z; Lenihan D; Plappert T; Englefield V; Fisch M; Ky B
Open Heart; 2017; 4(1):e000524. PubMed ID: 28123764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
